Oliver Gautschi
Oliver Gautschi
Unknown affiliation
Verified email at luks.ch
Cited by
Cited by
First-line crizotinib versus chemotherapy in ALK-positive lung cancer
BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ...
N Engl j Med 371, 2167-2177, 2014
Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
J Mazieres, S Peters, B Lepage, AB Cortot, F Barlesi, M Beau-Faller, ...
Journal of clinical oncology 31 (16), 1997-2003, 2013
Aurora kinases as anticancer drug targets
O Gautschi, J Heighway, PC Mack, PR Purnell, PN Lara, DR Gandara
Clinical Cancer Research 14 (6), 1639-1648, 2008
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open …
AT Shaw, TM Kim, L Crinò, C Gridelli, K Kiura, G Liu, S Novello, A Bearz, ...
The Lancet Oncology 18 (7), 874-886, 2017
Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort
J Mazières, G Zalcman, L Crinò, P Biondani, F Barlesi, T Filleron, ...
Journal of clinical oncology 33 (9), 992-999, 2015
Circulating deoxyribonucleic acid as prognostic marker in non–small-cell lung cancer patients undergoing chemotherapy
O Gautschi, C Bigosch, B Huegli, M Jermann, A Marx, E Chassé, ...
Journal of Clinical Oncology 22 (20), 4157-4164, 2004
Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation
O Gautschi, D Ratschiller, M Gugger, DC Betticher, J Heighway
Lung cancer 55 (1), 1-14, 2007
A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells
U Zangemeister-Wittke, SH Leech, RA Olie, AP Simões-Wüst, O Gautschi, ...
Clinical cancer research 6 (6), 2547-2555, 2000
Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins
O Gautschi, S Tschopp, RA Olie, SH Leech, AP Simoes-Wust, A Ziegler, ...
Journal of the National Cancer Institute 93 (6), 463-471, 2001
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
M Pless, R Stupp, HB Ris, RA Stahel, W Weder, S Thierstein, MA Gerard, ...
The Lancet 386 (9998), 1049-1056, 2015
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non–small-cell lung cancer: a model for assessing population-related pharmacogenomics
DR Gandara, T Kawaguchi, J Crowley, J Moon, K Furuse, M Kawahara, ...
Journal of clinical oncology 27 (21), 3540, 2009
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
M Delaunay, J Cadranel, A Lusque, N Meyer, V Gounant, D Moro-Sibilot, ...
European Respiratory Journal 50 (2), 2017
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
J Mazieres, F Barlesi, T Filleron, B Besse, I Monnet, M Beau-Faller, ...
Annals of Oncology 27 (2), 281-286, 2016
Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry
O Gautschi, J Milia, T Filleron, J Wolf, DP Carbone, D Owen, R Camidge, ...
Journal of Clinical Oncology 35 (13), 1403, 2017
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J Mazieres, A Drilon, A Lusque, L Mhanna, AB Cortot, L Mezquita, ...
Annals of Oncology 30 (8), 1321-1328, 2019
A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib
O Gautschi, C Pauli, K Strobel, A Hirschmann, G Printzen, S Aebi, ...
Journal of Thoracic Oncology 7 (10), e23-e24, 2012
Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic …
SL Smith, NL Bowers, DC Betticher, O Gautschi, D Ratschiller, PR Hoban, ...
British journal of cancer 93 (6), 719-729, 2005
Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients
JL Ramirez, C Sarries, PL de Castro, B Roig, C Queralt, D Escuin, ...
Cancer letters 193 (2), 207-216, 2003
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international …
RA Stahel, O Riesterer, A Xyrafas, I Opitz, M Beyeler, A Ochsenbein, ...
The lancet oncology 16 (16), 1651-1658, 2015
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
R Rosell, U Dafni, E Felip, A Curioni-Fontecedro, O Gautschi, S Peters, ...
The Lancet Respiratory Medicine 5 (5), 435-444, 2017
The system can't perform the operation now. Try again later.
Articles 1–20